CA
SRPT icon

Calton & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Calton & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,614
Closed -$209K – 291
2022
Q4 		$209K Buy
+1,614
New +$187K 0.08% 253
2021
Q1 		– Sell
-1,516
Closed -$258K – 429
2020
Q4 		$258K Buy
+1,516
New +$225K 0.05% 297
2020
Q1 		– Sell
-1,619
Closed -$209K – 375
2019
Q4 		$209K Buy
+1,619
New +$163K 0.04% 334

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Calton & Associates's SRPT Position: Q1 2023 in Review

Calton & Associates sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 1,614 shares — an estimated $209K sold.

Calton & Associates first reported a position in SRPT in Q4 2019 and held it in 3 quarters. The position peaked at $258K in Q4 2020. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • Calton & Associates reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Calton & Associates sold 1,614 Sarepta Therapeutics shares in Q1 2023, an estimated $209K.
  • Calton & Associates first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 3 quarters.
  • Calton & Associates's Sarepta Therapeutics position peaked at $258K in Q4 2020.
  • 425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Calton & Associates's 13F filing for Q1 2023, filed 19 Apr 2023.